Clinical Dilemmas in Inflammatory Bowel Disease - New Challenges

Informationen zum Autor Dr Corey Siegel, Director, Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, NH, USA. Dr Peter Irving, Consultant Gastroenterologist, Guy's and St Thomas' Hospital London. Prof David Rampton, Professor of Clinical Gastroenterology, Barts and The London, London. Prof Fergus Shanahan, Professor and Chairman, Department of Medicine/Director of Alimentary Pharmabiotic Centre, University College Cork, Ireland. Klappentext The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking.Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors. Zusammenfassung Unlike other books on IBD which focus on systematic diagnosis, treatment plans, etc. , this book addresses the key dilemmas that specialists face every day, providing a clinically focused analysis of controversial areas of IBD management, including emerging treatment therapies, surgical issues, and infection. Inhaltsverzeichnis List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD - study of coding variation or epigenetics? ( Miles Parkes ). 2 IBD in different ethnic groups: same or different? ( Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger ). Part 2: Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? ( Kiran K. Peddi and Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian Soon and Gilaad Kaplan ). 5 What to do about hepatitis B and hepatitis C in patients with IBD ( Morven Cunningham and Graham R. Foster ). 6 CMV in IBD - passenger or pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium difficile in IBD: Impact, Prevention and Treatment ( Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre- and synbiotics: placebo or panacea ( James O. Lindsay ). 9 Worms - light at the end of their burrow? ( John Leung and Joel V. Weinstock ). 10 Do we really need to vaccinate all patients with IBD? ( Gauree Gupta and Gil Y. Melmed ). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation exposure in IBD: how do we minimize the dangers? ( Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher ). 13 Surveillance colonoscopy in UC - what's the best way to do it? ( Matt Rutter ). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? ( Richard Logan and Venkataraman Subramanian ). 16 Why do we still use 5-ASAs in Crohns disease? ( Stephen Hanauer, Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the...

List of contents

List of Contributors.
 
Preface.
 
Part 1: Genes and Phenotype in IBD.
 
1 Which will take us further in IBD - study of coding variation or epigenetics? (Miles Parkes).
 
2 IBD in different ethnic groups: same or different? (Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger).
 
Part 2: Bugs and IBD - good, bad or indifferent?
 
3 How does the risk of infection influence management of IBD around the world? (Kiran K. Peddi and Ian Craig Lawrance).
 
4 Travelling with IBD (Ing Shian Soon and Gilaad Kaplan).
 
5 What to do about hepatitis B and hepatitis C in patients with IBD (Morven Cunningham and Graham R. Foster).
 
6 CMV in IBD - passenger or pathogen? (Ahmed Kandiel & Bret Lashner).
 
7 Clostridium difficile in IBD: Impact, Prevention and Treatment (Ashwin N. Ananthakrishnan and David G. Binion).
 
8 Pre- and synbiotics: placebo or panacea (James O. Lindsay).
 
9 Worms - light at the end of their burrow? (John Leung and Joel V. Weinstock).
 
10 Do we really need to vaccinate all patients with IBD? (Gauree Gupta and Gil Y. Melmed).
 
Part 3: Investigating IBD.
 
11 Biomarkers in IBD: myth or marvel? (Richard B. Gearry, Andrew S. Day).
 
12 Radiation exposure in IBD: how do we minimize the dangers? (Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher).
 
13 Surveillance colonoscopy in UC - what's the best way to do it? (Matt Rutter).
 
Part 4: Medical therapy.
 
5-ASA.
 
14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy).
 
15 Do 5ASAs prevent cancer? (Richard Logan and Venkataraman Subramanian).
 
16 Why do we still use 5-ASAs in Crohns disease? (Stephen Hanauer, Henit Yanai, Emma Calabrese).
 
Steroids.
 
17 Steroids in Crohn's disease: do the benefits outweigh the dangers? (A. Hillary Steinhart).
 
Immunomodulators.
 
18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? (Miles Sparrow).
 
19 Thiopurines and the sun: what should be done? (Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood).
 
20 Do thiopurines worsen risk and prognosis of cervical neoplasia? (Jeremy D. Sanderson and Melissa A. Smith).
 
21 Optimising use of methotrexate (Anna Foley and Peter R. Gibson).
 
22 Which calcineurin inhibitor and when? (A. Barney Hawthorne).
 
Biologics.
 
23 Are all anti-TNF agents the same? (Jennifer L. Jones).
 
24 One drug or two: Do patients on biologics need concurrent immunomodulation? (Glen A. Doherty and Adam S. Cheifetz).
 
25 How do we identify patients needing early aggressive therapy and what should we use? (Marc Ferrante and Séverine Vermeire).
 
26 What is the role of biologics in UC? (Joanna K. Law and Brian Bressler).
 
27 What can we do with Crohn's patients refractory to antiTNF therapy? (David T. Rubin).
 
28 Which EIMs respond to biologics? (Tina A. Mehta and CS Probert).
 
29 Use and abuse of biologics in pregnancy (Marla C. Dubinsky).
 
30 Is anti-TNF therapy safe to use in people with a history of malignancy? (Mark Lust and Simon Travis).
 
31 What and how should we tell patients about the risks of immunomodulators and biologics? (Corey A Siegel).
 
32 When, how and in whom should we stop biologics? (Edouard Louis, Jacques Belaiche, Catherine Reenaers).
 
Part 5: Other treatments.
 
33 Avoiding drug interactions (Tim Elliott and Peter M. Irving).
 
34 Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis? (Emmanouil Sinakos & Keith Lindor).
 <

Report

" Bottom Line : Clinical Dilemmas inInflammatory Bowel Disease: New Challengestargets the IBD clinicianand is a practical, well-written, easy-to-use text that will beinvaluable to all involved in the care of IBD patients, includinggastroenterologists, nurses, colorectal surgeons, anddieticians. Trainee gastroenterologists will find this textuseful both in IBD management and as a source for IBD clinicalpresentations. I highly recommend this text for anyone who isengaged in the day-to-day clinical care of patients withIBD." ( Gastroenterology , 1 December 2012)
"This is a timely update and expanded second edition that examinesmany newer clinical dilemmas in IBD. The short chapters are easy toabsorb and key opinion leaders offer interesting insights. Itcertainly justifies replacing the previous edition." (Doody s, 24February 2012)

Product details

• Authors: Peter Irving, Peter (St Thomas'''' Hospital Irving, Peter Siegel Irving, Pm Irving, David Rampton, Fergus Shanahan, Corey A. Siegel
• Assisted by: Core A Siegel (Editor), Corey A Siegel (Editor), Peter Irving (Editor), Irving Peter (Editor), David Rampton (Editor), David S. Rampton (Editor), David Rampton et al (Editor), Fergus Shanahan (Editor), Shanahan Fergus (Editor), Corey A. Siegel (Editor), Siegel Corey A. (Editor)
• Publisher: Wiley, John and Sons Ltd
• Languages: English
• Product format: Paperback / Softback
• Released: 11.11.2011
• EAN: 9781444334548
• ISBN: 978-1-4443-3454-8
• No. of pages: 288
• Series: Clinical Dilemmas (UK)
• Subjects: Natural sciences, medicine, IT, technology > Medicine > General; Medizin, Gastroenterologie, Gastroenterology, Medical Science